Synergistic antitumor activity of aspirin and erlotinib: Inhibition of p38 enhanced aspirin plus erlotinib-induced suppression of metastasis and promoted cancer cell apoptosis.

Hu, Xiu; Wu, Lin-Wen; Weng, Xu; Lin, Neng-Ming; Zhang, Chong

Hu, Xiu; Wu, Lin-Wen; Weng, Xu; Lin, Neng-Ming; Zhang, Chong.

Afiliación

Hu X; School of Medicine, Zhejiang University City College, Hangzhou, Zhejiang 310015, P.R. China.
Wu LW; College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, P.R. China.
Weng X; School of Medicine, Zhejiang University City College, Hangzhou, Zhejiang 310015, P.R. China.
Lin NM; College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, P.R. China.
Zhang C; Department of Clinical Pharmacology, Hangzhou First People's Hospital, Nanjing Medical University, Hangzhou, Zhejiang 310006, P.R. China.

Oncol Lett ; 16(2): 2715-2724, 2018 Aug.

Article en En | MEDLINE | ID: mdl-30013667